Please ensure Javascript is enabled for purposes of website accessibility

Should You Worry About Novavax's Vaccine Delay?

By Adria Cimino - Updated Jun 23, 2021 at 8:33AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Let's look to where the company might generate sales.

Investors expect Novavax (NVAX 2.00%) to file for Emergency Use Authorization for its coronavirus vaccine candidate soon. But the filing won't come as soon as everyone had hoped. In this Motley Fool Live video recorded on May 28, 2021, healthcare and cannabis bureau editor and analyst Olivia Zitkus and contributor Adria Cimino discuss whether the recently announced delay in Novavax's filing might hurt eventual vaccine sales.

Olivia Zitkus: Let's talk about a few slow rollers in the COVID vaccine race that we've been talking about for over a year now. Yeah. Top of mind for me is Novavax. They released their Q1 report on May 10. And in that report, the company outlined that it's still not quite ready to file with the FDA for Emergency Use Authorization. Could you explain what's going on here? Is there a reason to be worried? I mean, Novavax was I think one of the best healthcare stocks, if not the best healthcare performer of 2020. There might still be people hanging on to those gains who are wondering if they have reason to be worried. [laughs]

Adria Cimino: I would say it's disappointing but it's not worrisome, is what I would say. They had to show that their facilities can manufacture product on a commercial scale. All facilities can do that now. They have to complete final phases of testing to show the consistency of their processes. This is all part of their filing, and Novavax said it didn't expect to finish by the end of June. So just it wanted to give itself that little bit of a comfort. Rather than racing to be done or disappointing investors, they'd rather just extend and say, ''O.K., we're going to aim for the third quarter.'' So that's what they did. I don't think it's going to be much of an issue anyway. They already have their order from the U.S., and the U.S. already has enough vaccine doses for this year. The U.S. has actually been donating doses. So I really don't think it's a big deal and it's still in the near term. We're still going to have the conclusion of this whole Novavax story. Europe still needs doses, and they are having discussions with the European Commission, so that's a good sign there. If they can get something there, that will be great. So there's still a lot of reasons to be positive. There's reason to be positive for Novavax.

Adria Cimino has no position in any of the stocks mentioned. Olivia Zitkus has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$42.30 (2.00%) $0.83

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.